Javascript was detected to be disabled. Javascript is required for some functions on this website.

News Archive


Interventions for Ultra-Rare Disorders (URDs): How to Assess “Value for Money”?

Now available for download:

The “URD Consensus” documented as a peer-reviewed publication in the Journal of Market Access and Health Policy.

Read more …

Recent Scientific Presentations at the 19th Annual European ISPOR Congress in Vienna / Austria, October 29 – November 03, 2016

Now available for download:

Abstracts and presentations on “Comparing HTAs in Germany and UK”, “Budget Impact and Cost Drivers of Drugs for Rare and Ultra-Rare Diseases in Europe”, and key design elements of the SoPHI [Social Preferences for Health Interventions) Study (“European Social Preference Measurement [ESPM] Project”)

Read more …

Invitation to Stakeholders concerned with Economic Evaluation and Health Technology Assessments (HTAs)

Announcement: Heidelberg Health Economics Summer School 2016

Dear Colleague:

Following the positive feedback we received regarding last year’s Health Economics Summer School, we decided to offer a new program in 2016.

Read more …

The Social Value of Orphan Medicinal Products

Now online available: First public presentation and discussion of the European Social Preference Measurement (ESPM) project at the Multi-Stakeholder Symposium on improving patient access to rare disease therapies, organized by “Rare Diseases Europe” (EURORDIS) in Brussels, February 24, 2016.

Read more …

Can We Afford the Cost of Cancer Care?

Health care policy makers are increasingly worried by the increasing costs of cancer care. In particular, the average costs per patient of some new cancer treatments now exceed €10,000 per month. The inevitable concern about the future affordability of these treatments is aggravated by the fact that some of them have not even been shown to increase overall survival by any relevant margin – in fact, some of them improve progression-free survival only. On the one hand, almost 2.5 million people are newly diagnosed with cancer in the European Union each year, and the cost of cancer in Europe has been estimated to exceed 125 billion per year. On the other hand, substantial medical progress has been achieved in some areas, and research promises further improvements by targeting interventions using genetic information.

Against this background, a presentation at the German Cancer Research Center addressed key issues related to the future affordability, as well as measures taken internationally to ensure value for money, of cancer care.

Also see Recent Scientific Presentations.

Read more …